vTv Therapeutics Inc.
NASDAQ:VTVTBiotechnology
+$0.50 today
- Market cap
- $64.17M
- Beta
- 0.27
- P/E (TTM)
- 128.7
- EPS (TTM)
- $0.27
Volume 0.02M
Average 0.05M
VTVT Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
vTv Therapeutics Inc.NASDAQ: VTVT
Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026
Stock-based compensation outflow shrinks to $0
Q1 FY2026 stock-based compensation was $0, compared with $813K a year earlier. Trailing-twelve-month stock-based compensation was $1.96M.
Context
- Stock-based compensation increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly stock-based compensation holds near $0 or moves back toward the trailing-twelve-month quarterly average of $488.75K.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
USD · from the cash flow
- Latest · FY2025
- 3.78M USD
- Year-over-year change
- +36.9%
- 4-year CAGR
- +12.5%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 3.78M | +36.9% |
| FY2024 | 2024-12-31 | 2.76M | +74.7% |
| FY2023 | 2023-12-31 | 1.58M | — |
| FY2022 | 2022-12-31 | 0 | -100.0% |
| FY2021 | 2021-12-31 | 2.36M | — |
Stock-Based Compensation vs competitors
How VTVT compares with its peers on the latest reported figures
- VTVT's LTM Mar 2026 stock-based compensation of $1.96M is the 7th largest of the 9 companies compared; the peer median is $4.47M.
- Its year-over-year change of -41.6% is the 8th highest of 9, against a peer median of -32.9%.
- Stock-based compensation amounts to 5.3% of revenue for VTVT, versus a peer median of 26.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
OSTXOS Therapies Incorporated | LTM Mar 2026 | $4.27B | +453006.6% | — | — |
| LTM Mar 2026 | $2.67B | +116111.4% | -4.0% | — | |
| LTM Mar 2026 | $22.45M | -34.1% | +7.7% | 33.9% | |
| LTM Mar 2026 | $5.14M | -37.3% | +4.9% | 1543.3% | |
| LTM Jun 2026 | $3.79M | -50.8% | -5.5% | 18.1% | |
| LTM Mar 2026 | $2.72M | -37.2% | -10.8% | — | |
| LTM Mar 2026 | $1.96M | -41.6% | — | 5.3% | |
| LTM Mar 2026 | $1.79M | -31.8% | +5.7% | — | |
| LTM Mar 2026 | $367K | +43.4% | -60.2% | 16.0% | |
| Peer median (excluding VTVT) | $4.47M | -32.9% | -4.0% | 26.0% | |
Competitors are the stored peer set for VTVT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (17.73M) | (19.16M) | (20.25M) | (22.71M) | (31.08M) |
| Depreciation & Amortization | 89K | 92K | 90K | 89K | 16K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 2.36M | 0 | 1.58M | 2.76M | 3.78M |
| Change in Working Capital | 35K | 5.39M | 4.39M | (5.44M) | 1.89M |
| Accounts Receivables | 101K | (116K) | 71K | 40K | 0 |
| Inventory | (889K) | 0 | 0 | 0 | 0 |
| Accounts Payables | 1.83M | (856K) | 2.93M | 0 | 1.53M |
| Other Working Capital | (1.01M) | 6.36M | 1.39M | (5.48M) | 362K |
| Other Non-Cash Items | (4.06M) | (1.56M) | (4.89M) | (10K) | 142K |
| Operating Cash Flow | (19.31M) | (15.25M) | (19.08M) | (25.31M) | (25.26M) |
| Capital Expenditures | 0 | (21K) | 0 | 0 | 0 |
| Acquisitions (Net) | 0 | 0 | 4.4M | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 4.4M | 0 | 0 |
| Other Investing Activities | 0 | 0 | (4.4M) | 0 | 0 |
| Investing Cash Flow | 0 | (21K) | 4.4M | 0 | 0 |
| Debt Repayment | 172K | (808K) | (33K) | (191K) | (392K) |
| Common Stock Issued | 26.76M | 14.79M | 12.03M | 52.8M | 77.48M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 47K | 0 | 0 | 0 | 341K |
| Financing Cash Flow | 26.98M | 13.98M | 12M | 52.61M | 77.44M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 7.67M | (1.29M) | (2.68M) | 27.3M | 52.19M |
| Free Cash Flow | (19.31M) | (15.27M) | (19.08M) | (25.31M) | (25.26M) |
vTv Therapeutics Inc.
NASDAQ:VTVT
Intrinsic Alpha fair value
Locked
Current Price
$16.23
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.